|

30,000 MG01 +10,000 T521 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Inmunotek S.L.1

Indications

  • Asthma, Allergic1
  • Rhinoconjunctivitis1
  • Rhinitis, Allergic1
  • Asthma1

Other1 trial

Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.